SGO 2018: Putting PARP Inhibitor Perspectives Into Practice

March 28, 2018 9:28 pm

Achieving consensus on which poly (ADP-ribose) polymerase (PARP) inhibitor to use and when during management of ovarian cancer proved challenging Sunday for 4 oncologists who took attendees through a lively discussion of applying current standards from professional societies to everyday … Read more

SGO 2018: A Vaccine Shows Promise Against Ovarian Cancer

March 26, 2018 9:11 pm

A vaccine derived from a patient’s tumor cells, which enhances T-cell targeting of cancer cells, has shown promise against ovarian cancer.

This outcome of a phase 1 clinical trial was reported at the Society of Gynecologic Oncology’s 2018 Annual Meeting … Read more

Doctors Said Immunotherapy Would Not Cure Her Cancer. They Were Wrong.

February 21, 2018 7:16 pm

No one expected the four young women to live much longer. They had an extremely rare, aggressive and fatal form of ovarian cancer. There was no standard treatment.

The women, strangers to one another living in different countries, asked their … Read more

Clinical Trials Offer Promising New Treatments for Ovarian Cancer

February 5, 2018 9:10 pm

By: Deborah Zajchowski, PhD – Scientific Director, The Clearity Foundation

In the past three years, new hope has come to many women with ovarian cancer because of four new drugs that were approved for the treatment of this disease. These … Read more

BRCA1 Methylation Tied to Ovarian Cancer Risk

January 18, 2018 4:26 am

BRCA1 mutations are well-known to predispose to ovarian cancer risk. But now a new study, appearing in the Annals of Internal Medicine, suggests that methylation of normal BRCA1 genes might be a major ovarian cancer risk factor. In this Read more

Heated Abdominal Chemo Bath Improves Ovarian Cancer Survival

January 17, 2018 5:00 pm

By Gene Emery

A heated chemotherapy organ bath circulated throughout the abdomen after surgery can significantly prolong a woman’s survival with advanced ovarian cancer, according to doctors testing the new treatment.

Patients who underwent the experimental procedure at 8 hospitals … Read more

Women with Ovarian Cancer Who May Benefit from Maintenance Treatment

January 15, 2018 6:18 pm

Myriad Genetics and AstraZeneca have expanded their collaboration to conduct a study to identify women with advanced ovarian cancer who may benefit from maintenance treatment with Lynparza (olaparib) and Avastin (bevacizumab).

Myriad’s myChoice HRD Plus is a test for BRCA1 … Read more

Combinations May Be The Future Of Immunotherapy In Ovarian Cancer

January 12, 2018 10:27 pm

To date, trials testing the use of immunotherapy in the treatment of ovarian cancer yielded disappointing results. However, researchers are not giving up. Instead, they’re investigating to see if immunotherapy drugs – such as PD1 and PDL-1 inhibitors – can … Read more

FDA Grants Priority Review for Rucaparib

December 28, 2017 8:08 pm

The US Food and Drug Administration (FDA) has granted priority review status to rucaparib as maintenance therapy for women with recurrent ovarian cancer, according to the drug’s developer. The application is for women who are platinum sensitive, and in complete … Read more

Future Focus: Ovarian Cancer in 2018 and Beyond

December 14, 2017 3:49 pm

Oliver Dorigo, M.D., Ph.D., Associate Professor of Obstetrics and Gynecology (Oncology), Stanford University Medical Center, talks about the direction of research in the ovarian cancer field going into 2018 and beyond. He shares his excitement about trials that will further … Read more

Tumor Profiling Panel Undergoes Simultaneous FDA, CMS Review

December 9, 2017 12:04 am

The US Food and Drug Administration (FDA) has approved a cancer diagnostic test, FoundationOne CDx (F1CDx, Foundation Medicine), for use in detecting 300-plus genetic mutations in any solid tumor. At the same time, the Centers for Medicare & Medicaid Services … Read more

Precision Oncology or One Size Fits All?

November 1, 2017 5:42 pm

Platinum/taxane combinations are the most effective regimens for treatment of epithelial ovarian cancer. Response varies between patients, but because the molecular basis for resistance is not defined, patients receive so-called one size fits all therapy. In contrast, elucidation of the … Read more

Precision Medicine: A New Era for Ovarian Cancer

September 6, 2017 4:46 pm

By: Laura L. Holman, MD, MS

We’ve come a long way in treating ovarian cancer. This treatment has historically consisted of debulking surgery for nearly every patient, but it is evolving to become more informed and precise. Diagnostic laparoscopy, for … Read more

A Peek Into Big Data and Ovarian Cancer

July 31, 2017 7:33 pm

By: Annette McElhiney

On July 29, 2017, I celebrated 9 years since my IIIC ovarian cancer debulking surgery.  Because I’ve been so fortunate to be in remission, I spend hours each day researching, writing, and corresponding with other ovarian cancer … Read more

Roadblocks to Advancing Treatment of Rare Ovarian Cancers

July 26, 2017 4:37 pm

It is difficult for advances to be made in rare cancers because there are fewer patients. This makes it more challenging to conduct clinical trials for these diseases. Rare ovarian cancers are no exception to this.

In an interview with … Read more

PARP Inhibitors Changing the Landscape of Ovarian Cancer Treatment

July 11, 2017 5:53 pm

With the FDA approval of two new PARP inhibitor drugs since last year’s Ovarian Cancer National Conference, it’s no surprise the topic was of great interest at this year’s meeting in Chicago, and a standing-room-only crowd was on hand July … Read more

CT Technology Shows How Blood Flow Can Predict Ovarian Cancer Treatment

July 7, 2017 4:59 pm

Technology developed at Western University and Lawson Health Research Institute can provide a new window into whether or not patients are responding to treatment for advanced ovarian cancer. A multi-centre clinical trial has demonstrated that CT Perfusion, which measures blood … Read more

Avastin Gains Expanded FDA Approval for Platinum-Sensitive Ovarian Cancer

December 8, 2016 7:04 pm

Avastin (bevacizumab) gained an expanded FDA approval to treat patients with platinum-sensitive recurrent ovarian cancer as a part of a combination regimen with chemotherapy followed by continued use of the angiogenesis inhibitor, according to the drug developer, Genentech.

The approval … Read more

Profile-Matched Patient Assistance and Clinical Trial Options

May 2, 2016 8:38 pm

Clearity has taken steps to help accelerate molecular matching by enabling women to access the drugs their physicians prescribe to treat their ovarian cancer. The pilot Clearity Match Patient Assistance program that was recently announced helps subsidize the cost of … Read more

Molecular Profiling of Epithelial Ovarian Cancer

October 24, 2015 11:00 am

Epithelial ovarian cancer (EOC) is the most common cause of gynecological cancer death in the United States, with an estimated 21,290 new cases and 14,180 deaths estimated for 2015 (ACS 2015). The vast majority of women are diagnosed with advanced … Read more